Cormorant Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Cormorant Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22M	Hold	2,344,971	–	–	1.13%	25
2026 Q1	$22M	Hold	2,344,971	–	–	1.11%	25
2025 Q4	$19.1M	Sell	2,344,971 -30,029	-1%	-$371K	0.88%	24
2025 Q3	$30M	Hold	2,375,000	–	–	2.07%	14
2025 Q2	$16.4M	Hold	2,375,000	–	–	1.22%	19
2025 Q1	$12.6M	Hold	2,375,000	–	–	0.95%	26
2024 Q4	$28M	Hold	2,375,000	–	–	1.54%	19
2024 Q3	$49M	Buy	2,375,000 +350,000	+17%	+$17.9M	2.6%	10
2024 Q2	$91.6M	Hold	2,025,000	–	–	5.29%	2
2024 Q1	$79.5M	Buy	+2,025,000	New	+$49.9M	3.49%	7
2017 Q2	–	Sell	-56,203	Closed	-$13.9M	–	73
2017 Q1	$13.9M	Sell	56,203 -27,130	-33%	-$6.66M	2.02%	18
2016 Q4	$21.1M	Buy	83,333 +16,666	+25%	+$3.82M	2.85%	12
2016 Q3	$13.6M	Hold	66,667	–	–	1.5%	23
2016 Q2	$5.98M	Buy	+66,667	New	+$5.23M	0.85%	40

Other funds holding CRBP

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Cormorant Asset Management's CRBP Position: Q2 2026 in Review

Cormorant Asset Management held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 2,344,971 shares worth $22M. The position accounts for 1.13% of the portfolio, ranked #25.

Cormorant Asset Management first reported a position in CRBP in Q2 2016 and has held it in 14 quarters since. The position peaked at $91.6M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

Cormorant Asset Management held 2,344,971 shares of Corbus Pharmaceuticals worth $22M as of Q2 2026.
Cormorant Asset Management left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
Corbus Pharmaceuticals made up 1.13% of Cormorant Asset Management's portfolio in Q2 2026, its #25 holding.
Cormorant Asset Management first reported a position in Corbus Pharmaceuticals in Q2 2016 and has held it in 14 quarters since.
Cormorant Asset Management's Corbus Pharmaceuticals position peaked at $91.6M in Q2 2024.
107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.